Clinical Trial Update: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa [Phase 2]

View source ↗

Summary

The Phase II trial of BEZ235 (dactolisib) as monotherapy for malignant perivascular epithelioid cell tumor has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Perivascular Epithelioid Cell Tumor

Drugs mentioned

• BEZ235 (dactolisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malignant PEComa (Perivascular Epithelioid Cell Tumors) | Phase 2 | Status: WITHDRAWN